In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Hosted on MSN
Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy?
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to buy according to analysts. On December 19, TheFly reported that Cathie Wood’s ARK Investment has ...
) has been revised to $7.14 / share. This is an increase of 10.53% from the prior estimate of $6.46 dated December 3, 2025. The price target is an average of many targets provided by analysts. The ...
Recursion Pharmaceuticals (RXRX) is upgraded to Buy, driven by promising REC-4881 data and analyst optimism for FAP market potential. REC-4881's Phase 1b/2 results show a 43% median polyp burden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback